Question from Deputy Ciarán Ahern - PQ 31918-26
Deputy Ahern asked about the funding for the Alzheimer’s drug lecanemab. Read the HSE response.
- Published date:
- :
Browse and read HSE's latest publications, which include strategic plans, reports, official policies and codes, Parliamentary Question (PQ) responses, and board meeting minutes.
Deputy Ahern asked about the funding for the Alzheimer’s drug lecanemab. Read the HSE response.
Deputy O'Flynn asked whether any patients currently have access to omaveloxolone for Friedreich’s ataxia through compassionate use. Read the HSE response.
Deputy O'Flynn asked if the conversion of agency staff to direct employment has resulted in an increase in frontline staffing capacity. Read the HSE response.
Deputy O'Flynn asked if the absence of a standardised definition of medical necessity in surgical care creates a governance risk. Read the HSE response.
Deputy O'Flynn asked the number of adults with an intellectual disability currently living with a primary family carer aged over 65/70. Read the HSE response.
Deputy O'Flynn asked for a comparative cost per procedure between third-party insourcing, outsourcing via the National Treatment Purchase Fund.
Deputy O'Flynn asked about audits on the decision-making and approval processes under the Treatment Abroad Scheme since 2020. Read the HSE response.
Deputy Guirke asked about the free contraception scheme and steps being taken to ensure this scheme becomes genuinely inclusive. Read the HSE response.
Deputy Ó Murchú asked to revise the current medical card application forms to more clearly capture disability-related expenses. Read the HSE response.
Deputy O'Flynn asked if the agency premium is incorporated into workforce planning, budget allocations, or recruitment strategy. Read the HSE response.